# BioInnovation

> BioInnovation is a VC fund in Cambridge backing Biotechnology and Health Care. See 4 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United States
- Total investments: 4
- Last investment: Apr 2020
- Lead investor: 50%
- Last updated: Aug 2026
- Website: http://www.bioinnovation.co

BioInnovation is a VC fund in Cambridge focused on Biotechnology and Health Care. BioInnovation LLC, based in Cambridge, Massachusetts, is an early stage life sciences investment and consulting firm. We make seed investments, act as institutional co-founders, and provide strategic and operational services. As investors and entrepreneurs ourselves, we understand the needs of early-stage companies, and the end-to-end requirementsneeded to start, grow and build successful ventures.

## Contacts

5 contacts available for BioInnovation. Shizune tracks 2 team members at BioInnovation. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/bioinnovation?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 75% |
| Health Care | 2 | 50% |
| Therapeutics | 2 | 50% |
| Wellness | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 75% |
| Series B | 1 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Peter Parker | Founder and President | 0 | https://shizune.co/investors/profile/peter-parker |
| Susie Harborth | Co-Founder | 0 | https://shizune.co/investors/profile/susie-truong-harborth |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pandion Therapeutics | Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants.Pandion’s approach has the potential to more effectively induce and sustainresponse and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety. | $80M | Series B | Apr 01, 2020 |  |
| Cereius | Cereius is a pre-clinical stage company developing novel approaches to treating solid tumor brain metastasis. Cereius’ novel radiolabeling chemistries increase the uptake and retention of radionuclides in the target tumor while minimizing uptake by normal tissues, significantly enhancing the therapeutic index and diagnostic contrast of targetingagents. | $6.5M | Series A | Jul 25, 2018 |  |
| Pandion Therapeutics | Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants.Pandion’s approach has the potential to more effectively induce and sustainresponse and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety. | $58M | Series A | Jan 17, 2018 |  |
| Sentien Biotechnologies | Sentien Biotechnologies is a privately-owned, clinical-stage company developing novel cell therapies that restore balance to the immune system and transform treatment options for patients with systemic inflammatory diseases. The company's innovative blood conditioning approach has been proven to significantly enhance exposure and extendtherapeutic activity of Mesenchymal Stromal Cells (MSCs). By immobilizing MSCs in an extracorporeal device, their flagship SBI-101 product enables sustained, controlled dosage of secreted anti-inflammatory and regenerative properties that are unattainable by direct injection or intravenous infusion.Sentien Biotechnologies was established in 2008 and is headquartered in Lexington, Massachusetts, United States. | $12M | Series A | Apr 04, 2017 |  |

4 of 4 investments shown.

## Co-investors
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 2 deals together
- [Polaris Partners](https://shizune.co/investors/profile/polaris-partners) — VC Fund, 2 deals together
- [Roche Venture Fund](https://shizune.co/investors/profile/roche-venture-fund) — VC Fund, 2 deals together
- [SR One](https://shizune.co/investors/profile/sr-one) — VC Fund, 2 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 2 deals together
- [Access Biotechnology](https://shizune.co/investors/profile/access-biotechnology) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does BioInnovation invest in?

BioInnovation invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact BioInnovation?

Public channels for BioInnovation include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at BioInnovation?

The team at BioInnovation includes Peter Parker (Founder and President) and Susie Harborth (Co-Founder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co